RxDoctor Payments DataLook up a doctor →

Kathleen Thomas, DO

Rheumatology · Noblesville, INNPI 1467474031

Payments from drug & device makers

$510,504in general payments, 2019–2025

Across 819 payments — averaging $623.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$163K
  • Johnson & Johnson$124K
  • Novartis$101K
  • AbbVie$56K
  • UCB, Inc.$32K
  • Amgen$16K
  • plus $18K from 19 others

What the payments were for

  • Consulting fees$76,77115%
  • Speaking & faculty fees$363,29371%
  • Travel & lodging$53,62811%
  • Food & beverage$16,5643%
  • Education$2490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510,504 in reported general payments places this provider in the 95th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$2,174,223
Medicare patients
454
Services billed
182,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$337,814
Xeljanz XrTofacitinib Citrate34$226,027
Orencia ClickjectAbatacept33$186,690
Enbrel SureclickEtanercept18$133,307
Enbrel MiniEtanercept12$88,954
Hydroxychloroquine Sulfate558$26,191
MethotrexateMethotrexate Sodium506$15,130
Leflunomide150$11,109
Cevimeline Hcl23$5,833
Mycophenolate Mofetil20$4,996
Febuxostat11$3,632
Celecoxib29$3,110
Prednisone486$2,383
Ibandronate Sodium47$1,901
Pilocarpine Hcl17$1,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Colchicine$16$1,24514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →